IHS Chemical Week

Regions :: Middle East

Lonza Signs Manufacturing Deal with Immune Pharmaceuticals

12:04 AM MDT | July 19, 2011 | Deepti Ramesh

Lonza says it has signed an exclusive contract for the production of Immune Pharmaceuticals’ (Tel Aviv, Israel) human immunoglobulin monoclonal antibody, Bertilimumab, under investigation for the potential treatment of several inflammatory disorders. Lonza will produce phase 2 clinical trial material at its mammalian development and manufacturing facility, under the terms of the deal. Immune is a biopharmaceutical company focused on the development of next generation monoclonal antibodies addressing unmet medical needs in the treatment of cancer and...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa